Fennec Pharmaceuticals Inc (FENC)

[BioSpecialist]

Here is a Reason to be Optimistic about the Upcoming Phase 3 Results in June
.

Maybe this is the reason why Insider Holding a large Position in this undiscovered Goldmine and maybe why the new great Directors coming to Adherex . If Final Phase 3 results is positive then this Low Float Monster will explode like a Nuclear Bomb because the Drug has Orphan drug Status and it will be the only Drug for this Indication on the Market for a Long time because no Competitors out there . GLTA
---------

Adherex Announces Sodium Thiosulfate Clinical Study Update
~ Data have been submitted to ASCO 2014~

Adherex’s collaborator the Children’s Oncology Group (COG) posted top-line results from a Phase III trial of Adherex’s lead candidate STS to clinicaltrials.gov last week. The data are incomplete and no statistical analysis was performed. A full analysis of secondary endpoints such as event free survival and overall survival was not posted. Any interpretation should be limited until Adherex reports the full data, which is expected at the American Society of Clinical Oncology (ASCO) meeting in June 2014.

Posted Data, though Incomplete, is Encouraging. According to the posted results, the data regarding the frequency of patients with hearing loss is encouraging, and may support the primary endpoint after a full statistical analysis. The primary endpoint of the trial is hearing protection in pediatric oncology patients undergoing platinum-based chemotherapy.

The posted data show that out of 56 patients in the cisplatin arm of the study, 31 (55%) experienced hearing loss. For the 49 patients treated with STS and cisplatin, 14 (29%) experienced hearing loss. Information posted on the website is incomplete and final results may differ from those presented.

Adherex has announced that COG has already submitted an abstract for presentation at 2014 American Society of Clinical Oncology Meeting. The Company indicated that no other study data is available for public disclosure at this time.